MAVENCLAD als erste orale Kurzzeittherapie für schubförmig-remittierende MS in der Schweiz zugelassen 25.03.2019
![Marieke has MS on Twitter: "Yes yes here we go! Let's finish this b*tch. # Mavenclad #Year2 #Week3 #MS #DMT #WishMeLuck… " Marieke has MS on Twitter: "Yes yes here we go! Let's finish this b*tch. # Mavenclad #Year2 #Week3 #MS #DMT #WishMeLuck… "](https://pbs.twimg.com/media/ErtZSBKXEAcP7PM.jpg)
Marieke has MS on Twitter: "Yes yes here we go! Let's finish this b*tch. # Mavenclad #Year2 #Week3 #MS #DMT #WishMeLuck… "
MAVENCLAD 1. WAT IS MAVENCLAD EN WAARVOOR WORDT DIT MIDDEL GEBRUIKT? 2. WANNEER MAG U DIT MIDDEL NIET GEBRUIKEN OF MOET U ER EXT
Package leaflet: Information for the user MAVENCLAD 10 mg tablets cladribine Read all of this leaflet carefully before you start
Aan de minister voor Medische Zorg en Sport Postbus 20350 2500 EJ DEN HAAG Datum 16 januari 2018 Betreft GVS beoordeling cladrib
Package leaflet: Information for the user MAVENCLAD 10 mg tablets cladribine Read all of this leaflet carefully before you start
Package leaflet: Information for the user MAVENCLAD 10 mg tablets cladribine Read all of this leaflet carefully before you start
![Europäische Kommission erteilt Zulassung für Mavenclad® (Cladribin-Tabletten) | MERCK GesmbH, 25.08.2017 Europäische Kommission erteilt Zulassung für Mavenclad® (Cladribin-Tabletten) | MERCK GesmbH, 25.08.2017](https://www.ots.at/anhang/2017/08/25/PDF/PDF_20170825_OTS0080_0.layout.jpg)